Evidence map›Paper›PMID 36107359›Full record

ArticleCellular and molecular neurobiology2023

Acyl-Ghrelin Attenuates Neurochemical and Motor Deficits in the 6-OHDA Model of Parkinson's Disease.

Daniel Rees, Amy L Beynon, Mariah J Lelos, Gaynor A Smith, Luke D Roberts, Lyndsey Phelps, Stephen B Dunnett, Alwena H Morgan, Rowan M Brown, Timothy Wells and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Daniel ReesMolecular Neurobiology, Institute of Life Sciences, School of Medicine, Swansea University, Swansea, SA28PP, UK.ORCID http://orcid.org/0000-0003-0372-6096
Amy L BeynonMolecular Neurobiology, Institute of Life Sciences, School of Medicine, Swansea University, Swansea, SA28PP, UK.
Mariah J LelosSchool of Biosciences, Cardiff University, Cardiff, CF103AT, UK.ORCID http://orcid.org/0000-0001-7102-055X
Gaynor A SmithSchool of Biosciences, Cardiff University, Cardiff, CF103AT, UK.ORCID http://orcid.org/0000-0003-4332-8383
Luke D RobertsMolecular Neurobiology, Institute of Life Sciences, School of Medicine, Swansea University, Swansea, SA28PP, UK.
Lyndsey PhelpsSchool of Biosciences, Cardiff University, Cardiff, CF103AT, UK.
Stephen B DunnettSchool of Biosciences, Cardiff University, Cardiff, CF103AT, UK.ORCID http://orcid.org/0000-0003-1826-1578
Alwena H MorganMolecular Neurobiology, Institute of Life Sciences, School of Medicine, Swansea University, Swansea, SA28PP, UK.ORCID http://orcid.org/0000-0002-3441-5357
Rowan M BrownCollege of Engineering, Swansea University, Swansea, SA28PP, UK.ORCID http://orcid.org/0000-0003-3628-2524
Timothy WellsSchool of Biosciences, Cardiff University, Cardiff, CF103AT, UK.ORCID http://orcid.org/0000-0003-3618-0595
Jeffrey S DaviesMolecular Neurobiology, Institute of Life Sciences, School of Medicine, Swansea University, Swansea, SA28PP, UK. jeff.s.davies@swansea.ac.uk.ORCID http://orcid.org/0000-0002-4234-0033
Swansea University · GBCardiff University · GB

Funding

Medical Research Council MC_PC_16030/1Parkinson's UK F-1502Parkinson's UK K1008
6 · The paper itself

Abstract

The feeding-related hormone, acyl-ghrelin, protects dopamine neurones in murine 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-based models of experimental Parkinson's disease (PD). However, the potential protective effect of acyl-ghrelin on substantia nigra pars compacta (SNpc) dopaminergic neurones and consequent behavioural correlates in the more widely used 6-hydroxydopamine (6-OHDA) rat medial forebrain bundle (MFB) lesion model of PD are unknown. To address this question, acyl-ghrelin levels were raised directly by mini-pump infusion for 7 days prior to unilateral injection of 6-OHDA into the MFB with assessment of amphetamine-induced rotations on days 27 and 35, and immunohistochemical analysis of dopaminergic neurone survival. Whilst acyl-ghrelin treatment was insufficient to elevate food intake or body weight, it attenuated amphetamine-induced circling behaviour and SNpc dopamine neurone loss induced by 6-OHDA. These data support the notion that elevating circulating acyl-ghrelin may be a valuable approach to slow or impair progression of neurone loss in PD.

Indexed as

Parkinson DiseaseAmphetamineAnimalsDopamineDopaminergic NeuronsGhrelinMiceOxidopamineRatsacyl-ghrelinAmphetamineDopamineGhrelinOxidopamine6-OHDAAcyl-ghrelinParkinson’s disease

Identifiers

PMID36107359
PMCPMC10287784
OpenAlexW4295900844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.